3:53 PM
Feb 28, 2017
 |  BC Innovations  |  Distillery Therapeutics


INDICATION: Huntington's disease (HD)

Patient sample and mouse studies suggest inhibiting CSNK2A2 could help treat HD. Levels of CSNK2A2 were higher in striatal tissue samples from HD patients and striatal...

Read the full 129 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >